English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Goals  To determine whether patients with a pre-existing PPI treatment had a higher risk of poor evolution (recurrence or death) when diagnosed with a toxicogenic  Clostridium difficile  digestive infection.    Background  Previous studies identified pump proton inhibitor (PPI) prescription as a risk factor for  C. difficile  infection. The influence of PPI on the outcome of  C. difficile  infection is controversial.    Study  This was a retrospective monocentric cohort study. All cases of patients in our center with a symptomatic infection by a toxicogenic  C. difficile  strain during the years 2012 and 2013 were retrospectively analyzed. The primary endpoint was the occurrence of a recurrence or  C. difficile  infection -related death within 2 months after diagnosis.    Results  373 patients were included in this study (198 men and 175 women), with a mean age of 70.1 ± 18.6 years (2–100 years). Fourteen (3.7 %) patients died secondarily to  C. difficile  infection (median survival time 5 days), and 88 (23.6 %) experienced recurrence (after a median delay of 30 days). One hundred and ninety eight (53.1 %) patients were already receiving PPI at the time of the  C. difficile  infection (including 156 patients with a prescription >1 month). When analyzing separately men and women, male patients were more likely to experience recurrence or death in case of pre-existing PPI prescription [HR = 2.32 (1.26–4.27)]; this was not observed in female patients [HR = 0.62 (0.31–1.22)].    Conclusions  Pre-existing PPI therapy may increase the risk of recurrence or death in male patients with a toxicogenic  C. difficile  infection. PPI risk–benefit ratio should be carefully assessed.

Recurrence and death after Clostridium difficile infection: gender-dependant influence of proton pump inhibitor therapy